DGAP-Adhoc: Dermapharm Holding SE: binding offer to acquire Arkopharma Group
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover
Dermapharm Holding SE: binding offer to acquire Arkopharma Group
30-Jul-2022 / 20:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation – MAR)
Dermapharm Holding SE: binding offer to acquire Arkopharma Group
Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), offered to acquire 100% of the shares in Apharma TopCo SAS, headquartered in Carros, France, from private equity firm Montagu and minority shareholders of the target, for a purchase price approximating EUR 450 million.
Apharma TopCo SAS is the holding company of the Arkopharma Group, a provider of herbal OTC products and dietary supplements in France and other European countries. In the financial year 2021, Arkopharma Group achieved sales of approximately EUR 191 million. For the current financial year 2022, it forecasts sales of slightly over EUR 200 million.
The execution of the corresponding share purchase agreement is subject to the consultation of the works council of certain French companies of the Arkopharma Group. The Management Board expects the transaction to be completed at the beginning of January 2023.
>End of the Ad hoc announcement <
Contact
Investor Relations & Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
E-Mail: [email protected]
30-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Dermapharm Holding SE |
|
Lil-Dagover-Ring 7 |
|
82031 Grünwald |
|
Germany |
Phone: |
+49 (0)89 64 86-0 |
E-mail: |
[email protected] |
Internet: |
ir.dermapharm.de |
ISIN: |
DE000A2GS5D8 |
WKN: |
A2GS5D |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: |
1409691 |
|
End of Announcement |
DGAP News Service |
1409691 30-Jul-2022 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
467,12 |
572,42 |
700,88 |
793,83 |
942,91 |
1.024,78 |
1.135,35 |
EBITDA1,2 |
108,60 |
139,63 |
168,53 |
184,52 |
354,07 |
344,87 |
287,48 |
EBITDA-Marge3 |
23,25 |
24,39 |
24,05 |
23,24 |
37,55 |
33,65 |
|
EBIT1,4 |
92,12 |
107,51 |
119,51 |
136,85 |
298,47 |
243,69 |
182,89 |
EBIT-Marge5 |
19,72 |
18,78 |
17,05 |
17,24 |
31,65 |
23,78 |
16,11 |
Jahresüberschuss1 |
77,74 |
75,23 |
77,81 |
85,93 |
208,90 |
132,62 |
60,53 |
Netto-Marge6 |
16,64 |
13,14 |
11,10 |
10,82 |
22,16 |
12,94 |
5,33 |
Cashflow1,7 |
86,74 |
159,13 |
100,61 |
131,10 |
250,37 |
288,53 |
219,42 |
Ergebnis je Aktie8 |
1,56 |
1,41 |
1,43 |
1,59 |
3,89 |
2,49 |
1,16 |
Dividende8 |
0,00 |
0,77 |
0,80 |
0,88 |
2,17 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Dermapharm Holding |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2GS5D |
31,050 |
Halten |
1.671,73 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
13,50 |
24,31 |
0,56 |
17,26 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,40 |
7,62 |
1,47 |
9,08 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,05 |
0,88 |
2,83 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2024 |
27.08.2024 |
14.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-13,03% |
-21,45% |
-26,67% |
-31,40% |
|
|